The effect of aprepitant and race on the pharmacokinetics of cyclophosphamide in breast cancer patients

[1]  S. Marsh,et al.  Pyrosequencing of clinically relevant polymorphisms. , 2013, Methods in molecular biology.

[2]  R. Maziarz,et al.  Aprepitant Pharmacokinetics and Assessing the Impact of Aprepitant on Cyclophosphamide Metabolism in Cancer Patients Undergoing Hematopoietic Stem Cell Transplantation , 2012, Journal of clinical pharmacology.

[3]  M. Toi,et al.  Racial differences in acute toxicities of FEC 100 chemotherapy in patients with breast cancer. , 2009, Journal of Clinical Oncology.

[4]  J. Liao.  A New Approach for Outliers in a Bioavailability/Bioequivalence Study , 2007, Journal of biopharmaceutical statistics.

[5]  J. Lötsch,et al.  Pyrosequencing-based screening for genetic polymorphisms in cytochrome P450 2B6 of potential clinical relevance. , 2006, Pharmacogenomics.

[6]  M. Kris,et al.  American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  R. Gralla,et al.  Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  S. Rodenhuis,et al.  Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism , 2005, Cancer Chemotherapy and Pharmacology.

[9]  H. McLeod,et al.  CYP3A4 and CYP3A5 genotyping by Pyrosequencing , 2005, BMC Medical Genetics.

[10]  C. Lines,et al.  Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe , 2003, Clinical pharmacology and therapeutics.

[11]  C. Lines,et al.  Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone , 2003, Clinical pharmacology and therapeutics.

[12]  A. Boddy,et al.  Population pharmacokinetics of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF). , 2002, European journal of cancer.

[13]  W. Collard,et al.  Liquid chromatography-tandem mass spectrometric quantitation of cyclophosphamide and its hydroxy metabolite in plasma and tissue for determination of tissue distribution. , 2001, Journal of chromatography. B, Biomedical sciences and applications.

[14]  D. Greenblatt,et al.  CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[15]  D. Waxman,et al.  Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. , 2000, Biochemical pharmacology.

[16]  A. Boddy,et al.  Metabolism and Pharmacokinetics of Oxazaphosphorines , 2000, Clinical pharmacokinetics.

[17]  P. Beaune,et al.  Human CYP2B6: expression, inducibility and catalytic activities. , 1999, Pharmacogenetics.

[18]  D. Waxman,et al.  Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[19]  K. Thummel,et al.  IN VITRO AND IN VIVO DRUG INTERACTIONS INVOLVING HUMAN CYP 3 A , 1998 .

[20]  D. Waxman,et al.  Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[21]  M. Kinirons,et al.  Evidence of increased CPY3A4 activity in African Americans , 1996 .

[22]  L. Grochow,et al.  Quantitation of 4-hydroxycyclophosphamide/aldophosphamide in whole blood. , 1995, Journal of chromatography. B, Biomedical applications.

[23]  J. P. Singh,et al.  Methylprednisolone pharmacokinetics, cortisol response, and adverse effects in black and white renal transplant recipients. , 1995, Transplantation.

[24]  W. Jaeger,et al.  Clinical importance of hepatic cytochrome P450 in drug metabolism. , 1995, Drug metabolism reviews.

[25]  G. F. Weber,et al.  Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. , 1993, Cancer research.

[26]  B D Kahan,et al.  Demographic factors influencing cyclosporine pharmacokinetic parameters in patients with uremia: Racial differences in bioavailability , 1992, Clinical pharmacology and therapeutics.

[27]  D. Alberts,et al.  Plasma pharmacokinetics of cyclophosphamide and its cytotoxic metabolites after intravenous versus oral administration in a randomized, crossover trial. , 1987, Cancer research.

[28]  R. Aur,et al.  Cyclophosphamide‐induced hemorrhagic cystitis in children with leukemia , 1975, Cancer.